跳转到主要内容
search
API
Active Pharmaceutical Ingredients
导航
Main navigation
关于我们
产品
APIs
仿制药
功能
研究和开发
制造业
客户服务
资源
白皮书
文章
新闻
活动
网络研讨会
更新
联系我们
XCEED 登录
Select your language
English
简体中文
Español
Português
日本語
快速连接
白皮书
面包屑
家
白皮书
White Paper
白皮书
文章
新闻
活动
網絡研討會
更新
2021
ROXADUSTAT - a multipronged development strategy
2021
Dr.Reddy's Apremilast API and finished formulation offerings.
2021
Dr. Reddy’s Fosaprepitant API offerings
2021
Apixaban API – ready-to-compress granules and finished dosage forms
2021
Apalutamide API – an attractive NCE-1 opportunity for generic pharma companies
2021
Colloidal Iron Complex Formulations – Understanding and Developing the Process
2021
Rivaroxaban from Dr.Reddy’s: Full basket offerings of API and Finished formulations
2021
Dr. Reddy's Mirabegron API offering in both alpha and amorphous form
2021
Palbociclib – how a novel process development approach provides IP advantages
2020
Dr. Reddy's Elagolix API offering leverages a well rounded Quality by Design approach
2020
Gliflozins – an attractive opportunity for early market access
2020
Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings
2020
Dr. Reddy’s Flow Chemistry experts share their perspectives in panel discussion of Chemistry Today
2020
A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine
2020
Famotidine and Nizatidine APIs: NDMA controlled, customized particle distribution, supply chain security
2020
Sitagliptin case: Enhancing formulation development and early market access through an integrated understanding of key API attributes
2020
Sugammadex Sodium – The impact of an integrated understanding from API to formulation on injectable formulation success
2019
Meeting the New Regulatory Requirements in Sartan API Production
